Please contact us for more information or to learn if you are eligible to participate.
Purpose of the study is to evaluate the efficacy and safety of rivaroxaban to reduce the risk of major thrombotic vascular events in patients with symptomatic peripheral artery disease undergoing lower extremity revascularization procedures.
Mahesh Changlani, MD
Bayer Health Care Pharmaceuticals, Inc.
Type of Trial